RE:RE:Lack of Updates Resverlogix and ZenithHi GV. I guess I'm pretty excited about the scientific potential but frustrated by the market capitalization.
I got really excited when I fitted the regression curves to the MACE data from the combined SUSTAIN and MACE trials. The data included patients with diabetes mellitus and cardiovascular disease (CVD).
This was posted previously.
- Within the test group (treated with rvx-208 + Crestor) the MACE events were 5.1% at the end point of the trial which was at day 210 (over 1/2 a year).
- Within the control group (treated with Crestor only) at day 210 the MACE level was 20.8% and had experienced exponential acceleration from trial day 150.
- When I fitted a regression curve of the form of a linear component and a natural logarithmic component (ln) to the test data the statistical fit to the real data was R-squared = 89% and significant at less than p = .01.
- For the test group I projected this out to 360 days and the estimate of test group MACE (rvx-208+Crestor) was 6.9%. So knowing that forecasts have high variability lets say we pick test group MACE at between 8 and 12%.
- Using the 12% as very conservative estimate at day 360 this yields a relative risk reduction of 42% and is highly significant when compared to the control group (Crestor only) way back at day 210.
- So this begs the question of the effectiveness of Crestor only treatment starting back at day 150 and accelerating.
So that will be a boring read for everyone but exciting data.
Then Jkj you did a post on Feb 23rd at 4:07 about the launch of new drugs for heart disease being launched this fall by various BP. The post was
- Drug and biotech giants such as Pfizer Inc. PFE, +0.03% , Amgen Inc. AMGN, +0.10% , Merck & Co. Inc. and an alliance between Sanofi Inc. SNY, +0.40% and Regeneron Pharmaceuticals Inc. REGN, -0.10% are developing this new class of cholesterol drugs that is due to start hitting the market later this year.
- Read more at https://www.stockhouse.com/companies/bullboard/t.rvx/resverlogix-corp#1ZhlbILlgqY7ShGo.99
What strikes me about this is that
AstraZeneca (Crestor) is not there. They must have plans in the works and they are probably available. So I wonder where the CRESTOR + rvx-208 is going to fit into this equation given the huge impact on MACE.
On a separate point re Zenith being a private company I believe that shareholders still have rights and that because Zenith was spun out of a publically traded company these rights may be significant. I'm sure that Eastern and NGN know they have rights. If anyone has access to a good investment lawyer of advisor it would be great to get an opinion on this. Either way, it seems Zenith is irrelevant for at least 2 or 3 years.
Have a great night. I'm going out to the shed to get a baseball bat to crack my knuckles so it is too painful to post. LOL
GLTA
Toinv :)